Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice

This publication has 40 references indexed in Scilit:

• Murine models of human neuropathic pain
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
• Constitutive Activity at the Cannabinoid CB₁Receptor Is Required for Behavioral Response to Noxious Chemical Stimulation of TRPV1: Antinociceptive Actions of CB1 Inverse Agonists
  Journal of Neuroscience, 2008
• Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese Rats
  Diabetes, 2008
• SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients
  Diabetes Care, 2008
• Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes
  Annals of Medicine, 2008
• The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Taurine Counteracts Oxidative Stress and Nerve Growth Factor Deficit in Early Experimental Diabetic Neuropathy
  Experimental Neurology, 2001
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
  FEBS Letters, 1994
• Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats
  Clinical Immunology and Immunopathology, 1992
• Ethical guidelines for investigations of experimental pain in conscious animals
  Pain, 1983